Drug Trial Radar · NCT06137911
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
Last checked: Nov 19, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Sep 26, 2021
Primary completion
Nov 9, 2022
Study completion Nov 9, 2022
Sponsor
- Lead sponsor
- Guangzhou JOYO Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of JYP0061 in healthy adult subjects. The main questions it aims to answer are: safety and tolerability of JYP0061 in healthy subjects, the pharmacokinetic characteristics after single and multiple doses and the effect of food on the pharmacokinetic characteristics. Participants will be treated with JYP0061 orally and safety and pharmacokinetic evaluations will be conducted according to the protocol.
Conditions
- Healthy Subjects
Interventions
JYP0061Drug
JYP0061 orally administered
placeboDrug
Placebo orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- The peak plasma concentration that JYP0061 achieves after dosing.Time frame: up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui District Central Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.